LYELL IMMUNOPHARMA INC's ticker is LYEL and the CUSIP is 55083R104. A total of 80 filers reported holding LYELL IMMUNOPHARMA INC in Q1 2022. The put-call ratio across all filers is 0.02 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $110,639,000 | +12.4% | 15,093,969 | 0.0% | 42.56% | +56.4% |
| Q2 2022 | $98,413,000 | +29.1% | 15,093,969 | 0.0% | 27.22% | +35.7% |
| Q1 2022 | $76,225,000 | -34.8% | 15,093,969 | 0.0% | 20.06% | +37.8% |
| Q4 2021 | $116,827,000 | -48.0% | 15,093,969 | -0.5% | 14.55% | -52.5% |
| Q3 2021 | $224,483,000 | -8.9% | 15,167,757 | 0.0% | 30.66% | -5.2% |
| Q2 2021 | $246,324,000 | – | 15,167,757 | – | 32.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WuXi AppTec Co., Ltd. | 7,682,156 | $11,139,126 | 47.74% |
| MWG Management Ltd. | 20,162,332 | $29,235,381 | 31.93% |
| Orland Properties Ltd | 15,093,969 | $21,886,255 | 16.63% |
| Foresite Capital Management IV, LLC | 8,325,000 | $12,071,250 | 8.11% |
| Opaleye Management Inc. | 1,670,000 | $2,421,500 | 0.55% |
| MIC Capital Management UK LLP | 1,740,569 | $2,523,825 | 0.55% |
| Alphabet Inc. | 5,865,125 | $8,504,431 | 0.43% |
| HSG Holding Ltd | 3,045,997 | $4,995,435 | 0.18% |
| Orbimed Advisors | 6,405,098 | $9,287,392 | 0.18% |
| Ikarian Capital, LLC | 526,066 | $762,796 | 0.13% |